Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | $555.60 | Strong Buy | $640.00 | +15.19% | a day ago | |
Analyst RankingTop 19% #936 out of 5104 analysts Average Return+7.73% Win Rate49%36 out of 73 Risk vs RewardPoor Good Analyst ColorTruist Securities's Srikripa Devarakonda raised their price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) by 10.3% from $580 to $640 on 2025/11/19. The analyst maintained their Strong Buy rating on the stock. Devarakonda attributed their price target hike on Madrigal Pharmaceuticals to increased confidence in Rezdiffra's potential, specifically in MASH F4 subtype, following data at AASLD. The analyst detailed that their take on the stock assumes peak adjusted MASH F4 sales of $1.5B, up from their prior $750M estimate.. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to ? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.